-
Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022
Sep 9, 2025, 16:22 PM -
Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach
Sep 9, 2025, 16:22 PM -
Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma
Sep 9, 2025, 16:22 PM -
Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of Abrocitinib vs. Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Sep 9, 2025, 16:22 PM -
Development and Assessment of a Portability Strategy for Computable Operational Definitions
Sep 9, 2025, 16:22 PM -
Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Optimizing HER2+ Breast Cancer Treatment Pathways in Italian Oncological Centers
Sep 9, 2025, 16:22 PM -
Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?
Sep 9, 2025, 16:22 PM -
Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel
Sep 9, 2025, 16:22 PM -
Health Equity in Economic Analyses of Person-Centered Care: A Systematic Review
Sep 9, 2025, 16:22 PM -
A New Approach for Modeling the Complexity of the Impact of Caring Using the Family and Caregiving Effects
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways
Sep 9, 2025, 16:22 PM -
Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials
Sep 9, 2025, 16:22 PM -
A Review of NICE Technology Appraisals in Oncology Including Economic Evaluations With Time-Varying Network Meta-Analysis
Sep 9, 2025, 16:22 PM -
Understanding the Impact of the NICE Severity Modifier: A Targeted Review of Oncology Submissions
Sep 9, 2025, 16:22 PM -
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM -
Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement
Sep 9, 2025, 16:22 PM
